Global Leukemia Academy

Emerging and Practical Concepts and Controversies in Leukemias

Overview

In recent years progress in the molecular understanding of acute leukemias has led to greatly improved comprehension of these diseases, and novel approved therapies are changing treatment paradigms. Aptitude Health has developed the Global Leukemia Academy and is organizing a series of meetings in 2020 to help physicians better understand how the emerging therapies and concepts are being adapted globally, and to address barriers between innovation and implementation for patient care.

Date and Location

8–9 July 2020
Virtual Meeting

Meeting Content

View the slides and watch the video of the Day 1
ALL Plenary Session

View the slides and watch the video of the Day 2
ALL Pediatric Session

View the slides and watch the video of the Day 2
ALL Adult Session

Faculty

Patrick Brown

Patrick A. Brown, MD

Johns Hopkins University
School of Medicine, USA

Fatih Demirkan

Fatih Demirkan, MD

Dokuz Eylul University, Turkey

Elias Jabbour

Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center, USA

Hale Ӧren

Hale Ӧren, MD

Dokuz Eylul University, Turkey

Rob Pieters

Rob Pieters, MD, PhD

Princess Máxima Center for Pediatric Oncology,
University of Utrecht, The Netherlands

Josep Ribera

Josep Ribera, MD

Catalan Institute of Oncology, University Hospital Germans Trias i Pujol, Spain

Andre Schuh

Andre Schuh, MD

Princess Margaret Cancer Centre, Canada

Agenda

The virtual program ran over 2 days.
Day 1: Plenary Session ALL
Day 2: Parallel breakout sessions, Pediatric and Adult ALL
DAY 1:
Virtual Plenary sessions
Time UTC+3 Title Speaker
Wednesday, 8 July 2020 from 15.00 – 19.00 (UTC+3) 15.00 – 15.10 Welcome and meeting overview
Introduction to the voting system
Elias Jabbour
Fatih Demirkan
  15.10 – 15.25 Review of prognostic value of MRD in ALL Elias Jabbour
  15.25 – 15.40 How and when to check for MRD in ALL Josep‑Maria Ribera
  15.40 – 15.55 CR1 vs CR2 – where is MRD control more useful and how to achieve it? Elias Jabbour
  15.55 – 16.10 AYA ALL patients – what is the current treatment approach for this diverse patient population? Rob Pieters
  16.10 – 16.25 Bispecific T-cell engagers as post-reinduction therapy improves survival in pediatric and AYA B-ALL Patrick Brown
  16.25 – 16.45 Coffee break  
  16.45 – 17.00 Genetic variants in ALL – Ph+ and Ph-like Andre Schuh
  17.00 – 17.45 Panel discussion on the role of HSCT
• Experience of HSCT in the region
• Pros and cons of HSCT
• How does COVID-19 influence your approach?
• Discussion and voting
Fatih Demirkan
Fatih Demirkan, Andre Schuh
All faculty
All faculty
  17.45 – 18.25 Debate on CD19-targeted approaches
• CAR T
• Monoclonal antibodies and bispecifics
• Discussion and voting
Josep‑Maria Ribera
Elias Jabbour
All faculty
  18.25 – 18.55 Emerging data and the management of ALL patients during COVID-19
• Presentation
• Panel discussion
Fatih Demirkan
Elias Jabbour
All faculty
  18.55 – 19.00 Session close Elias Jabbour
Fatih Demirkan


DAY 2:
Virtual Breakout 1: Pediatric ALL patients
Time UTC+3 Title Speaker
Thursday, 9 July 2020 from 15.00 – 17.10 (UTC+3) 15.00 – 15.15 Session opening
• Educational ARS questions for the audience
Rob Pieters
  15.15 – 15.35 First-line treatment of pediatric ALL
• Presentation
• Q&A
Rob Pieters
  15.35 – 15.55 Current treatment options for relapsed ALL in children, including HSCT considerations
• Presentation
• Q&A
Hale Ören
  15.55 – 16.15 Bispecific T-cell engagers for pediatric ALL
• Presentation
• Q&A
Patrick Brown
  16.15 – 16.55 Case-based panel discussion
Management of long- and short-term toxicities
• Overview of long-term toxicities
• Patient case presentation
Panelists: Rob Pieters, Hale Ören, Patrick Brown, Akif Yesilipek, Sema Anak
Rob Pieters, Hale Ӧren
All panelists
  16.55 – 17.10 Session close
• Educational ARS questions for the audience
Rob Pieters

DAY 2:
Virtual Breakout 2: Adult ALL patients
Time UTC+3 Title Speaker
Thursday, 9 July 2020 from 15.00 – 17.00 (UTC+3) 15.00 – 15.15 Session opening
• Educational ARS questions for the audience
Elias Jabbour
  15.15 – 15.35 Optimizing first-line therapy in adult and older ALL – integration of immunotherapy into frontline regimens
• Presentation
• Q&A
Elias Jabbour
  15.35 – 15.55 Current treatment options for relapsed ALL in adult and elderly patients
• Presentation
• Q&A
Fatih Demirkan
  15.55 – 16.45 Case-based panel discussion
Management of long- and short-term toxicities and treatment selection in adult and elderly patients
Panelists: Elias Jabbour, Fatih Demirkan, Andre Schuh, Josep-Maria Ribera

Fatih Demirkan, Andre Schuh

All panelists

  16.45 – 17.00 Session close
• Educational ARS questions for the audience
Elias Jabbour